Detterbeck Frank C, Mase Vincent J, Li Andrew X, Kumbasar Ulas, Bade Brett C, Park Henry S, Decker Roy H, Madoff David C, Woodard Gavitt A, Brandt Whitney S, Blasberg Justin D
Department of Thoracic Surgery, Yale University School of Medicine, New Haven, CT, USA.
Department of General Surgery, Yale University School of Medicine, New Haven, CT, USA.
J Thorac Dis. 2022 Jun;14(6):2357-2386. doi: 10.21037/jtd-21-1824.
Clinical decision-making for patients with stage I lung cancer is complex. It involves multiple options (lobectomy, segmentectomy, wedge, stereotactic body radiotherapy, thermal ablation), weighing multiple outcomes (e.g., short-, intermediate-, long-term) and multiple aspects of each (e.g., magnitude of a difference, the degree of confidence in the evidence, and the applicability to the patient and setting at hand). A structure is needed to summarize the relevant evidence for an individual patient and to identify which outcomes have the greatest impact on the decision-making.
A PubMed systematic review from 2000-2021 of outcomes after lobectomy, segmentectomy and wedge resection in generally healthy patients is the focus of this paper. Evidence was abstracted from randomized trials and non-randomized comparisons with at least some adjustment for confounders. The analysis involved careful assessment, including characteristics of patients, settings, residual confounding etc. to expose degrees of uncertainty and applicability to individual patients. Evidence is summarized that provides an at-a-glance overall impression as well as the ability to delve into layers of details of the patients, settings and treatments involved.
In healthy patients there is no short-term benefit to sublobar resection lobectomy in randomized and non-randomized comparisons. A detriment in long-term outcomes is demonstrated by adjusted non-randomized comparisons, more marked for wedge than segmentectomy. Quality-of-life data is confounded by the use of video-assisted approaches; evidence suggests the approach has more impact than the resection extent. Differences in pulmonary function tests by resection extent are not clinically meaningful in healthy patients, especially for multi-segmentectomy lobectomy. The margin distance is associated with the risk of recurrence.
A systematic, comprehensive summary of evidence regarding resection extent in healthy patients with attention to aspects of applicability, uncertainty and effect modifiers provides a foundation on which to build a framework for individualized clinical decision-making.
I期肺癌患者的临床决策很复杂。它涉及多种选择(肺叶切除术、肺段切除术、楔形切除术、立体定向体部放疗、热消融),需要权衡多种结果(如短期、中期、长期)以及每个结果的多个方面(如差异大小、证据的可信度、对当前患者和情况的适用性)。需要一种结构来总结个体患者的相关证据,并确定哪些结果对决策影响最大。
本文重点对2000年至2021年PubMed上关于一般健康患者肺叶切除术、肺段切除术和楔形切除术后结果的系统评价。证据摘自随机试验和对混杂因素进行了至少一些调整的非随机比较。分析包括仔细评估,包括患者特征、环境、残余混杂因素等,以揭示不确定性程度和对个体患者的适用性。总结的证据提供了一目了然的总体印象,以及深入研究患者、环境和所涉及治疗细节层次的能力。
在随机和非随机比较中,对于健康患者,亚肺叶切除 肺叶切除术没有短期益处。调整后的非随机比较显示长期结果存在不利影响,楔形切除术比肺段切除术更明显。生活质量数据因使用视频辅助方法而混淆;有证据表明该方法的影响大于切除范围。在健康患者中,切除范围对肺功能测试的差异在临床上没有意义,尤其是对于多段切除 肺叶切除术。切缘距离与复发风险相关。
对健康患者切除范围的证据进行系统、全面的总结,关注适用性、不确定性和效应修饰因素等方面,为构建个体化临床决策框架奠定了基础。